

## **Bluestar Adisseo Company**

### **2025 Annual Report of Independent Directors**

#### **Ms. Zhixiang SUN**

In 2025, as independent director of Bluestar Adisseo Company ("the Company"), according to the *Company Law, Management Measures for Independent Directors of Listed Companies, Listing Rules of Shanghai Stock Exchange, the Articles of Association of Bluestar Adisseo Company ("AOA")* and *Bluestar Adisseo Company Rules for the Work of the Independent Director*, I fulfilled our duties in a diligent and conscientious manner, deeply understood the Company operation situation, actively attended related meetings, and earnestly deliberated all proposals of Board of Directors and Special Committee, thus fully playing the role of independent director and protecting the interests of the Company and shareholders, especially the small and medium shareholders. My 2025 annual work report of independent director is as follows:

#### **1. Basic information on independent director**

Ms. Sun was born in 1967, Chinese. I hold a Bachelor of Laws from Fudan University and a master's degree in International Economic Law from Fudan University. I was a Senior Visiting Fellow at Harvard University, USA.

With over 30 years of experience in legal consulting, Ms. Sun has extensive expertise in areas such as investment and financing, corporate affairs, and securities transactions. My professional tenure includes roles as Lawyer at Shanghai Foreign Economic Law Firm, China Legal Advisor at Yao Helen Law Firm Singapore, Head of International Finance Department at Shanghai Xinmin Law Firm, and currently serves as Senior Partner at Shanghai Pudong Law Firm. Since January 2021, I has been an Independent Director of MicroPort CardioFlow Medtech Corporation (listed on the Hong Kong Stock Exchange, stock code: HK02160); since May 2023, an Independent Director of Shanghai Baosight Software Co., Ltd. (listed on the Shanghai Stock Exchange, stock code: 600845); and since June 2024, an Independent Director of Shanghai Foreign Service Holdings Group Co., Ltd. (listed on the Shanghai Stock Exchange, stock code: 600662).

Since December 2025, Ms. Sun has been the Independent Director of the Company and the member of the Audit, Risk and Compliance Committee.

#### Confirmation of independence

As an independent director of the Company, I have the qualifications of independent directors and the independence required by laws and regulations. There is no employment relationship, transaction relationship, kinship and other situations affecting our independence with the company, its main shareholders, and actual controllers, and I can maintain objective and independent professional judgment in performing our duties.

#### **2. Annual performance of independent directors**

I have faithfully fulfilled my duties as an independent director, acted with diligence and responsibility, and actively participated in the board of directors and special committee meetings organized by the company in 2025. I have exercised my voting rights with an objective and responsible attitude, expressed clear opinions on relevant proposals, and ensured that the board's decisions are in the best interests of the listed company as a whole and protect the legitimate rights and interests of minority shareholders. I have not exercised the special powers stipulated in the *Measures for the Administration of Independent Directors of Listed Companies*.

## 2.1. Information on attending/Observing the meetings

In 2025, the Company held 9 meetings of the Board of Directors (8 meetings held through communication voting), 8 meetings of Audit Committee, 3 meetings of Strategic and ESG Committee\* (the "Strategic Committee"). There are 5 shareholders' meetings held in 2025. The following is a summary of my attendance at meetings.

### 2.1.1 Participation in board of directors and shareholders' meetings

Name of directos	Attendance at Board Meeting						Attendance at General meetings
	Required attendance at Board meetings in the term of office this year	Attendance in Person	Participation by communications	Attendance by proxy	Absence	Consecutively Absent from two meetings	Attendance frequency at the general meeting of shareholders
Zhixiang SUN	2	0	1	0	0	No	0

### 2.1.2 Participation in special committees and independent directors committee

Name of directos	Name of Special Committees	Required attendance	Attendance in person	Attendance by proxy	Absence
Zhixiang SUN	Audit Committee	1	1	0	0
	Strategic Committee	1*	1	0	0
	Independent Directors Committee	0	0	0	0

\* Note: During my tenure in 2025, the company held 1 Strategic Committee meeting. On 22nd December 2025, the Company held expanded Strategic Committee meeting and invited all directors to attend.

## 2.2. Information on the site work

In 2025, I attended company meetings and engaged in in-depth exchanges with the company's management team. This allowed me to promptly familiarize myself with and grasp the company's operational and developmental situation. Leveraging my professional knowledge and corporate management experience, I provided constructive opinions and suggestions on relevant board proposals, fully playing the role of guidance and supervision, and promoting the standardized operation of the company's internal management work. The key performance situations are briefly described as follows.

In December 2025, I held separate discussions with the company's chairman HAO Zhigang, CFO Virginie, and Board Secretary CAI Yun to understand the company's operation, financial management, corporate governance and other aspects.

### **2.3. Communication with internal audit and accounting firms**

In December 2025, I attended the Audit, Risk and Compliance Committee meeting, listened to the annual audit plan report by the accounting firm KPMG and the internal audit plan for 2026 presented by the Internal Audit Department, and had detailed discussions.

### **2.4. Cooperation between listed companies and independent directors in their work**

The management of the Company paid high attention to communication with independent directors. The Company provided periodic information on the Company's production and operation and the progress of major issues via monthly management report as well as periodical meetings and responded timely on issues raised, thus ensured a comprehensive condition and support for independent directors to perform our duties. Meanwhile, the Company has also carried out comprehensive and in-depth communication and explanation for the formulation, implementation and evaluation of executive remuneration policies, allowing a comprehensive support to remuneration committee to perform their key duties.

To understand the independent directors' evaluations and opinions on the functioning of the board of directors, the Company has organized and conducted the 2025 Board of Directors' Performance Evaluation. Through a questionnaire, the Company collected the independent directors' evaluations, opinions, and suggestions on the board's operations, thereby laying the foundation for improving the work of the board and enabling the independent directors to better fulfill their duties.

## **3. Overall Evaluation and Suggestions**

Since taking office in December 2025, as an independent director of the company, I have adhered to the principle of integrity, been diligent and responsible, maintained independence in my work, and played my due role in ensuring the company's standardized operation and improving the corporate governance structure.

In 2026, I will continuously follow the diligent and faithful principles, earnestly carry out our duties, to play an effective role in decision-making and supervision as independent directors; and I will protect the legitimate rights and interests of the Company and all shareholders, especially minority shareholders, thus making contributions to the development of the Company.

(In case of discrepancies between the English version and the Chinese version of this announcement, the Chinese version, officially published and disclosed, shall prevail.)